At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,200 enrolled
Drug / intervention
Compound Edaravone Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled PhaseⅢTrial
In Brief
A Phase 3 clinical trial evaluating Compound Edaravone Injection and Edaravone Injection for Acute Ischemic Stroke. Completed, enrolled 1,200 participants across 48 sites.
Detailed Summary
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionDec 2016
TodayJul 2026
First PostedApr 30, 2015
Enrollment StartMay 1, 2015
Primary CompletionDec 1, 2016
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 11.2 years ago
Interventions
Compound Edaravone Injectiondrug
Edaravone Injectiondrug